Review



fcgr3a polyclonal antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Proteintech fcgr3a polyclonal antibody
    Fcgr3a Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 77 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fcgr3a+polyclonal+antibody/CD16+Antibody/10__1096_slash_fj__202500034rr-81-73-79
    Average 95 stars, based on 77 article reviews
    fcgr3a polyclonal antibody - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Gene Expression:

    Article Title: Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single‐Cell RNA Sequencing
    Article Snippet: These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens. ... The primary antibodies used included Collagen Type III (N- terminal) Polyclonal antibody (22734- 1- AP, Proteintech, 1:1000), MMP3 Polyclonal antibody (17873- 1- AP, Proteintech, 1:100), MMP1 Polyclonal antibody (10371- 2- AP, Proteintech, 1:100), S100A10 Polyclonal antibody (11250- 1- AP, Proteintech, 1:400), TIMD4 Polyclonal antibody (12008- 1- AP, Proteintech, 1:200), CNRIP1 Polyclonal antibody (16827- 1- AP, Proteintech, 1:200), C1QA Monoclonal antibody (67063- 1- IG, Proteintech, 1:100), CSF1R Polyclonal antibody (25949- 1- AP, Proteintech, 1:50), FCGR3A Polyclonal antibody (16559- 1- AP, Proteintech, 1:100), and MRC1 Polyclonal antibody (18704- 1- AP, Proteintech, 1:100).. The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.

    Article Title: Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single‐Cell RNA Sequencing
    Article Snippet: These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.. The primary antibodies used included Collagen Type III (N‐terminal) Polyclonal antibody (22734‐1‐AP, Proteintech, 1:1000), MMP3 Polyclonal antibody (17873‐1‐AP, Proteintech, 1:100), MMP1 Polyclonal antibody (10371‐2‐AP, Proteintech, 1:100), S100A10 Polyclonal antibody (11250‐1‐AP, Proteintech, 1:400), TIMD4 Polyclonal antibody (12008‐1‐AP, Proteintech, 1:200), CNRIP1 Polyclonal antibody (16827‐1‐AP, Proteintech, 1:200), C1QA Monoclonal antibody (67063‐1‐IG, Proteintech, 1:100), CSF1R Polyclonal antibody (25949‐1‐AP, Proteintech, 1:50), FCGR3A Polyclonal antibody (16559‐1‐AP, Proteintech, 1:100), and MRC1 Polyclonal antibody (18704‐1‐AP, Proteintech, 1:100).. The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.

    Expressing:

    Article Title: Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single‐Cell RNA Sequencing
    Article Snippet: These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens. ... The primary antibodies used included Collagen Type III (N- terminal) Polyclonal antibody (22734- 1- AP, Proteintech, 1:1000), MMP3 Polyclonal antibody (17873- 1- AP, Proteintech, 1:100), MMP1 Polyclonal antibody (10371- 2- AP, Proteintech, 1:100), S100A10 Polyclonal antibody (11250- 1- AP, Proteintech, 1:400), TIMD4 Polyclonal antibody (12008- 1- AP, Proteintech, 1:200), CNRIP1 Polyclonal antibody (16827- 1- AP, Proteintech, 1:200), C1QA Monoclonal antibody (67063- 1- IG, Proteintech, 1:100), CSF1R Polyclonal antibody (25949- 1- AP, Proteintech, 1:50), FCGR3A Polyclonal antibody (16559- 1- AP, Proteintech, 1:100), and MRC1 Polyclonal antibody (18704- 1- AP, Proteintech, 1:100).. The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.

    Article Title: Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single‐Cell RNA Sequencing
    Article Snippet: These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.. The primary antibodies used included Collagen Type III (N‐terminal) Polyclonal antibody (22734‐1‐AP, Proteintech, 1:1000), MMP3 Polyclonal antibody (17873‐1‐AP, Proteintech, 1:100), MMP1 Polyclonal antibody (10371‐2‐AP, Proteintech, 1:100), S100A10 Polyclonal antibody (11250‐1‐AP, Proteintech, 1:400), TIMD4 Polyclonal antibody (12008‐1‐AP, Proteintech, 1:200), CNRIP1 Polyclonal antibody (16827‐1‐AP, Proteintech, 1:200), C1QA Monoclonal antibody (67063‐1‐IG, Proteintech, 1:100), CSF1R Polyclonal antibody (25949‐1‐AP, Proteintech, 1:50), FCGR3A Polyclonal antibody (16559‐1‐AP, Proteintech, 1:100), and MRC1 Polyclonal antibody (18704‐1‐AP, Proteintech, 1:100).. The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.

    Marker:

    Article Title: Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single‐Cell RNA Sequencing
    Article Snippet: These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens. ... The primary antibodies used included Collagen Type III (N- terminal) Polyclonal antibody (22734- 1- AP, Proteintech, 1:1000), MMP3 Polyclonal antibody (17873- 1- AP, Proteintech, 1:100), MMP1 Polyclonal antibody (10371- 2- AP, Proteintech, 1:100), S100A10 Polyclonal antibody (11250- 1- AP, Proteintech, 1:400), TIMD4 Polyclonal antibody (12008- 1- AP, Proteintech, 1:200), CNRIP1 Polyclonal antibody (16827- 1- AP, Proteintech, 1:200), C1QA Monoclonal antibody (67063- 1- IG, Proteintech, 1:100), CSF1R Polyclonal antibody (25949- 1- AP, Proteintech, 1:50), FCGR3A Polyclonal antibody (16559- 1- AP, Proteintech, 1:100), and MRC1 Polyclonal antibody (18704- 1- AP, Proteintech, 1:100).. The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.

    Article Title: Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single‐Cell RNA Sequencing
    Article Snippet: These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.. The primary antibodies used included Collagen Type III (N‐terminal) Polyclonal antibody (22734‐1‐AP, Proteintech, 1:1000), MMP3 Polyclonal antibody (17873‐1‐AP, Proteintech, 1:100), MMP1 Polyclonal antibody (10371‐2‐AP, Proteintech, 1:100), S100A10 Polyclonal antibody (11250‐1‐AP, Proteintech, 1:400), TIMD4 Polyclonal antibody (12008‐1‐AP, Proteintech, 1:200), CNRIP1 Polyclonal antibody (16827‐1‐AP, Proteintech, 1:200), C1QA Monoclonal antibody (67063‐1‐IG, Proteintech, 1:100), CSF1R Polyclonal antibody (25949‐1‐AP, Proteintech, 1:50), FCGR3A Polyclonal antibody (16559‐1‐AP, Proteintech, 1:100), and MRC1 Polyclonal antibody (18704‐1‐AP, Proteintech, 1:100).. The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.

    Control:

    Article Title: Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single‐Cell RNA Sequencing
    Article Snippet: These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens. ... The primary antibodies used included Collagen Type III (N- terminal) Polyclonal antibody (22734- 1- AP, Proteintech, 1:1000), MMP3 Polyclonal antibody (17873- 1- AP, Proteintech, 1:100), MMP1 Polyclonal antibody (10371- 2- AP, Proteintech, 1:100), S100A10 Polyclonal antibody (11250- 1- AP, Proteintech, 1:400), TIMD4 Polyclonal antibody (12008- 1- AP, Proteintech, 1:200), CNRIP1 Polyclonal antibody (16827- 1- AP, Proteintech, 1:200), C1QA Monoclonal antibody (67063- 1- IG, Proteintech, 1:100), CSF1R Polyclonal antibody (25949- 1- AP, Proteintech, 1:50), FCGR3A Polyclonal antibody (16559- 1- AP, Proteintech, 1:100), and MRC1 Polyclonal antibody (18704- 1- AP, Proteintech, 1:100).. The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.

    Article Title: Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single‐Cell RNA Sequencing
    Article Snippet: These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.. The primary antibodies used included Collagen Type III (N‐terminal) Polyclonal antibody (22734‐1‐AP, Proteintech, 1:1000), MMP3 Polyclonal antibody (17873‐1‐AP, Proteintech, 1:100), MMP1 Polyclonal antibody (10371‐2‐AP, Proteintech, 1:100), S100A10 Polyclonal antibody (11250‐1‐AP, Proteintech, 1:400), TIMD4 Polyclonal antibody (12008‐1‐AP, Proteintech, 1:200), CNRIP1 Polyclonal antibody (16827‐1‐AP, Proteintech, 1:200), C1QA Monoclonal antibody (67063‐1‐IG, Proteintech, 1:100), CSF1R Polyclonal antibody (25949‐1‐AP, Proteintech, 1:50), FCGR3A Polyclonal antibody (16559‐1‐AP, Proteintech, 1:100), and MRC1 Polyclonal antibody (18704‐1‐AP, Proteintech, 1:100).. The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.

    Immunohistochemistry:

    Article Title: Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single‐Cell RNA Sequencing
    Article Snippet: These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens. ... The primary antibodies used included Collagen Type III (N- terminal) Polyclonal antibody (22734- 1- AP, Proteintech, 1:1000), MMP3 Polyclonal antibody (17873- 1- AP, Proteintech, 1:100), MMP1 Polyclonal antibody (10371- 2- AP, Proteintech, 1:100), S100A10 Polyclonal antibody (11250- 1- AP, Proteintech, 1:400), TIMD4 Polyclonal antibody (12008- 1- AP, Proteintech, 1:200), CNRIP1 Polyclonal antibody (16827- 1- AP, Proteintech, 1:200), C1QA Monoclonal antibody (67063- 1- IG, Proteintech, 1:100), CSF1R Polyclonal antibody (25949- 1- AP, Proteintech, 1:50), FCGR3A Polyclonal antibody (16559- 1- AP, Proteintech, 1:100), and MRC1 Polyclonal antibody (18704- 1- AP, Proteintech, 1:100).. The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.

    Article Title: Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single‐Cell RNA Sequencing
    Article Snippet: These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.These sequential steps were performed to optimize the immunostaining process and facilitate accurate visualization of the target antigens.. The primary antibodies used included Collagen Type III (N‐terminal) Polyclonal antibody (22734‐1‐AP, Proteintech, 1:1000), MMP3 Polyclonal antibody (17873‐1‐AP, Proteintech, 1:100), MMP1 Polyclonal antibody (10371‐2‐AP, Proteintech, 1:100), S100A10 Polyclonal antibody (11250‐1‐AP, Proteintech, 1:400), TIMD4 Polyclonal antibody (12008‐1‐AP, Proteintech, 1:200), CNRIP1 Polyclonal antibody (16827‐1‐AP, Proteintech, 1:200), C1QA Monoclonal antibody (67063‐1‐IG, Proteintech, 1:100), CSF1R Polyclonal antibody (25949‐1‐AP, Proteintech, 1:50), FCGR3A Polyclonal antibody (16559‐1‐AP, Proteintech, 1:100), and MRC1 Polyclonal antibody (18704‐1‐AP, Proteintech, 1:100).. The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.The following day, the sections underwent TBS rinsing before the introduction of secondary antibodies.



    Similar Products

    95
    Proteintech fcgr3a polyclonal antibody
    Fcgr3a Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fcgr3a+polyclonal+antibody/CD16+Antibody/10__1096_slash_fj__202500034rr-81-73-79
    Average 95 stars, based on 1 article reviews
    fcgr3a polyclonal antibody - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    92
    OriGene rabbit anti cd16
    Primers for Each Gene for PCR Analysis
    Rabbit Anti Cd16, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fcgr3a+polyclonal+antibody/CD16+(FCGR3A)+Rabbit+Polyclonal+Antibody/pmc09078433-71-38-35
    Average 92 stars, based on 1 article reviews
    rabbit anti cd16 - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    Image Search Results


    Primers for Each Gene for PCR Analysis

    Journal: Journal of Inflammation Research

    Article Title: The Role of Bone Morphogenetic Protein 4 in Microglial Polarization in the Process of Neuropathic Pain

    doi: 10.2147/JIR.S356531

    Figure Lengend Snippet: Primers for Each Gene for PCR Analysis

    Article Snippet: All sections were rinsed in 0.2%Triton X-100 mixed with 5% donkey serum for 40 min at room temperature and then incubated overnight with primary antibodies at 4°C at the following dilutions: mouse anti-CD11b (SM262PS, 1:50, OriGene, MD, US), rabbit anti-CD16 (1:50, Affinity) and rabbit anti-ARG1 (1:100, Affinity).

    Techniques:

    Exogenous BMP4-induced allodynia, microglial activation and polarization. ( A ) PWT in rats after intrathecal BMP4 application showed a significant effect on time: F (4.143, 66.29) = 16.09, P<0.01, left; F (3.960, 63.35) = 12.67, P<0.01, right, intrathecal application: F (1, 16) = 161.3, P<0.01, left; F (1, 16) = 160.5, P<0.01, right and interaction: F (7, 112) = 11.76, P<0.01, left; F (7, 112) = 5.653, P<0.01, right. Compared with the Sham group, rats in the BMP4 group developed a significant decrease in bilateral PWT for the whole first week, P<0.01, n=9 at each time point for both groups. ( B ) Representative Western blotting showed a sustained increase of CD11b (P<0.01) and CD16 (P<0.01) expressions for the whole 1st week in the BMP4 group compared with the Sham group. Meanwhile, ARG-1 levels increased at day 1 (P<0.01) and day 4 (P<0.01), then fell below the levels of the Sham group (P<0.01). n=3 for each column. ( C and D ) Double-immunofluorescence further detected that compared with the Sham group (P7), CD11b expression was elevated in the dorsal horn of spinal cord after BMP4 treatment. Moreover, expressions of CD16 and ARG-1 showed similar pattern with Western blotting results, which were both mainly accumulated with CD11b + cells. n=3 for each column. Two-way ANOVA, followed by a Bonferroni test ( A ) and one-way ANOVA, followed by Sidak’s multiple comparisons test ( B – D ) were performed to analyze the statistical differences. *Represented P<0.05 and **Represented P<0.01 compared with the Sham group.

    Journal: Journal of Inflammation Research

    Article Title: The Role of Bone Morphogenetic Protein 4 in Microglial Polarization in the Process of Neuropathic Pain

    doi: 10.2147/JIR.S356531

    Figure Lengend Snippet: Exogenous BMP4-induced allodynia, microglial activation and polarization. ( A ) PWT in rats after intrathecal BMP4 application showed a significant effect on time: F (4.143, 66.29) = 16.09, P<0.01, left; F (3.960, 63.35) = 12.67, P<0.01, right, intrathecal application: F (1, 16) = 161.3, P<0.01, left; F (1, 16) = 160.5, P<0.01, right and interaction: F (7, 112) = 11.76, P<0.01, left; F (7, 112) = 5.653, P<0.01, right. Compared with the Sham group, rats in the BMP4 group developed a significant decrease in bilateral PWT for the whole first week, P<0.01, n=9 at each time point for both groups. ( B ) Representative Western blotting showed a sustained increase of CD11b (P<0.01) and CD16 (P<0.01) expressions for the whole 1st week in the BMP4 group compared with the Sham group. Meanwhile, ARG-1 levels increased at day 1 (P<0.01) and day 4 (P<0.01), then fell below the levels of the Sham group (P<0.01). n=3 for each column. ( C and D ) Double-immunofluorescence further detected that compared with the Sham group (P7), CD11b expression was elevated in the dorsal horn of spinal cord after BMP4 treatment. Moreover, expressions of CD16 and ARG-1 showed similar pattern with Western blotting results, which were both mainly accumulated with CD11b + cells. n=3 for each column. Two-way ANOVA, followed by a Bonferroni test ( A ) and one-way ANOVA, followed by Sidak’s multiple comparisons test ( B – D ) were performed to analyze the statistical differences. *Represented P<0.05 and **Represented P<0.01 compared with the Sham group.

    Article Snippet: All sections were rinsed in 0.2%Triton X-100 mixed with 5% donkey serum for 40 min at room temperature and then incubated overnight with primary antibodies at 4°C at the following dilutions: mouse anti-CD11b (SM262PS, 1:50, OriGene, MD, US), rabbit anti-CD16 (1:50, Affinity) and rabbit anti-ARG1 (1:100, Affinity).

    Techniques: Activation Assay, Western Blot, Immunofluorescence, Expressing

    Exogenous BMP4 induced a distinct pattern of M1/M2 gene expressions. RT-PCR analysis showed that M1-gene markers, including CD16, TNF-α and MHC-II, significantly increased throughout the whole 1st week, while M2-gene markers including ARG-1, CD-204 and IL-4 increased at an early stage (P1 or P4), then all fell to the Sham level at day 7. n=3 for each time point for both groups. One-way ANOVA, followed by Sidak’s multiple comparisons test were performed to analyze the statistical differences. *Represented P<0.05 and **Represented P<0.01 compared with the Sham group.

    Journal: Journal of Inflammation Research

    Article Title: The Role of Bone Morphogenetic Protein 4 in Microglial Polarization in the Process of Neuropathic Pain

    doi: 10.2147/JIR.S356531

    Figure Lengend Snippet: Exogenous BMP4 induced a distinct pattern of M1/M2 gene expressions. RT-PCR analysis showed that M1-gene markers, including CD16, TNF-α and MHC-II, significantly increased throughout the whole 1st week, while M2-gene markers including ARG-1, CD-204 and IL-4 increased at an early stage (P1 or P4), then all fell to the Sham level at day 7. n=3 for each time point for both groups. One-way ANOVA, followed by Sidak’s multiple comparisons test were performed to analyze the statistical differences. *Represented P<0.05 and **Represented P<0.01 compared with the Sham group.

    Article Snippet: All sections were rinsed in 0.2%Triton X-100 mixed with 5% donkey serum for 40 min at room temperature and then incubated overnight with primary antibodies at 4°C at the following dilutions: mouse anti-CD11b (SM262PS, 1:50, OriGene, MD, US), rabbit anti-CD16 (1:50, Affinity) and rabbit anti-ARG1 (1:100, Affinity).

    Techniques: Reverse Transcription Polymerase Chain Reaction

    Noggin relieved allodynia, attenuated microglial activation, and changed the polarized pattern after SNL. ( A ) PWT in rats receiving intrathecal Noggin application after SNL showed a significant effect on time: F (3.463, 55.41) = 162.3, P<0.01, intrathecal application: F (1, 16) = 44.85, P<0.01 and interaction: F (7, 112) = 3.540, P<0.01. Compared with the SNL group, Noggin application provided marked pain relief at day 3, day 4, day 5 and day 7 after SNL. n=9 at each time point for both groups. ( B and C ) Representative Western blotting showed SNL induced CD11b and CD16 upregulation at the first week, while ARG-1 expression remained unchanged compared with the Sham group; Moreover, Noggin effectively decreased the CD11b expressions at P1 and P4 and the CD16 expressions consecutively for the whole week. Simultaneously, the ARG-1 levels significantly elevated from P1 to P7 after Noggin treatment. n=3 for each column. Two-way ANOVA, followed by a Bonferroni test (A) and one-way ANOVA, followed by Sidak’s multiple comparisons test (B and C) were performed to analyze the statistical differences. **Represented P<0.01 compared with the Sham group, # Represented P<0.05 and ## Represented P<0.01 compared with the SNL group.

    Journal: Journal of Inflammation Research

    Article Title: The Role of Bone Morphogenetic Protein 4 in Microglial Polarization in the Process of Neuropathic Pain

    doi: 10.2147/JIR.S356531

    Figure Lengend Snippet: Noggin relieved allodynia, attenuated microglial activation, and changed the polarized pattern after SNL. ( A ) PWT in rats receiving intrathecal Noggin application after SNL showed a significant effect on time: F (3.463, 55.41) = 162.3, P<0.01, intrathecal application: F (1, 16) = 44.85, P<0.01 and interaction: F (7, 112) = 3.540, P<0.01. Compared with the SNL group, Noggin application provided marked pain relief at day 3, day 4, day 5 and day 7 after SNL. n=9 at each time point for both groups. ( B and C ) Representative Western blotting showed SNL induced CD11b and CD16 upregulation at the first week, while ARG-1 expression remained unchanged compared with the Sham group; Moreover, Noggin effectively decreased the CD11b expressions at P1 and P4 and the CD16 expressions consecutively for the whole week. Simultaneously, the ARG-1 levels significantly elevated from P1 to P7 after Noggin treatment. n=3 for each column. Two-way ANOVA, followed by a Bonferroni test (A) and one-way ANOVA, followed by Sidak’s multiple comparisons test (B and C) were performed to analyze the statistical differences. **Represented P<0.01 compared with the Sham group, # Represented P<0.05 and ## Represented P<0.01 compared with the SNL group.

    Article Snippet: All sections were rinsed in 0.2%Triton X-100 mixed with 5% donkey serum for 40 min at room temperature and then incubated overnight with primary antibodies at 4°C at the following dilutions: mouse anti-CD11b (SM262PS, 1:50, OriGene, MD, US), rabbit anti-CD16 (1:50, Affinity) and rabbit anti-ARG1 (1:100, Affinity).

    Techniques: Activation Assay, Western Blot, Expressing

    Noggin decreased M1-gene levels and induced a late-stage elevation of M2-gene levels after SNL. The mRNA levels of M1 and M2 subtype were determined by the RT-PCR method. The mRNA relative expressions from the Sham group were set as reference (equal to 1.0). As for the M1 genes, a significant increase in gene expressions were detected in CD16 from P1 to P7 and TNF-α from P4 to P7 in the SNL group compared with the Sham group, except for the MHC-II, which stayed unchanged. Then, in the SNL+NOG group, Noggin application markedly decreased CD16 and TNF-α levels for the 1st week. As for the M2 genes, SNL induced statistical elevation of ARG-1 from P4 and P7 and CD204 from P1 to P7, while IL-4 stayed comparable with the Sham group. Then, in the SNL+NOG group, Noggin treatment prominently increased ARG-1 at P7, CD204 at P4 and P7 and IL-4 at P7. n=3 for each time point. One-way ANOVA, followed by Sidak’s multiple comparisons test were performed to analyze the statistical differences. *Represented P<0.05 and **Represented P<0.01 compared with the Sham group; # Represented P<0.05 and ## Represented P<0.01 compared with the SNL group.

    Journal: Journal of Inflammation Research

    Article Title: The Role of Bone Morphogenetic Protein 4 in Microglial Polarization in the Process of Neuropathic Pain

    doi: 10.2147/JIR.S356531

    Figure Lengend Snippet: Noggin decreased M1-gene levels and induced a late-stage elevation of M2-gene levels after SNL. The mRNA levels of M1 and M2 subtype were determined by the RT-PCR method. The mRNA relative expressions from the Sham group were set as reference (equal to 1.0). As for the M1 genes, a significant increase in gene expressions were detected in CD16 from P1 to P7 and TNF-α from P4 to P7 in the SNL group compared with the Sham group, except for the MHC-II, which stayed unchanged. Then, in the SNL+NOG group, Noggin application markedly decreased CD16 and TNF-α levels for the 1st week. As for the M2 genes, SNL induced statistical elevation of ARG-1 from P4 and P7 and CD204 from P1 to P7, while IL-4 stayed comparable with the Sham group. Then, in the SNL+NOG group, Noggin treatment prominently increased ARG-1 at P7, CD204 at P4 and P7 and IL-4 at P7. n=3 for each time point. One-way ANOVA, followed by Sidak’s multiple comparisons test were performed to analyze the statistical differences. *Represented P<0.05 and **Represented P<0.01 compared with the Sham group; # Represented P<0.05 and ## Represented P<0.01 compared with the SNL group.

    Article Snippet: All sections were rinsed in 0.2%Triton X-100 mixed with 5% donkey serum for 40 min at room temperature and then incubated overnight with primary antibodies at 4°C at the following dilutions: mouse anti-CD11b (SM262PS, 1:50, OriGene, MD, US), rabbit anti-CD16 (1:50, Affinity) and rabbit anti-ARG1 (1:100, Affinity).

    Techniques: Reverse Transcription Polymerase Chain Reaction